Navigation Links
Stason Pharmaceuticals Inc. announces Kansas City expansion, adds human health capabilities
Date:11/8/2013

KANSAS CITY, Kan., Nov. 8, 2013 /PRNewswire/ -- Stason Pharmaceuticals, Inc. announced today that it is expanding into Kansas City by moving its brand division from Irvine, Calif. to Kansas City, Kan.  A new entity has been developed, KC Specialty Therapeutics LLC, in which the new assets will be placed to focus on research and development of new chemical entities for humans.

"Stason Pharmaceuticals has been very impressed with the biosciences opportunities in the Kansas City region since moving Stason Animal Health's national headquarters here earlier this year," said Diana Wood, vice president of corporate development for Stason Pharmaceuticals and CEO for KC Specialty Therapeutics LLC. "The KC Animal Health Corridor and broader life sciences community have been incredibly supportive."

Today's announcement comes just 90 days after Stason Pharmaceutical's animal division, Stason Animal Health, announced it was relocating its corporate headquarters to the KC Animal Health Corridor.

KC Specialty Therapeutics LLC will locate alongside Stason Animal Health at the Bioscience & Technology Business Center located on the University of Kansas Medical Center campus.  Over the next year, the company will create job opportunities in Kansas City and continue to grow its presence over time.

"We are thrilled that Stason Pharmaceuticals values our region's strong biosciences business environment," said Bob Marcusse, president and CEO, Kansas City Area Development Council. "We look forward to seeing both Stason Pharmaceuticals and KC Specialty Therapeutics grow in our region."

About Stason Pharmaceuticals
Stason Pharmaceuticals entered the commercial generic market in 1994 and today continues to manufacture and market these products through a global network of distributors. Stason entered the contract manufacturing arena in 2000 to provide manufacturing support to other pharmaceutical companies, and in 2008, Stason launched its Brand Division. Headquartered in Southern California, the Stason group employs approximately 120 people worldwide. http://www.stasonpharma.com/

About KC Specialty Therapeutics LLC
KC Specialty Pharma is focused on the development of new chemical entities in human orphan drug indications for which there is no available treatment.  Orphan drugs are defined as those that treat less than 200,000 in the US. 

About Greater Kansas City
Home to 2.5 million people, the Kansas City region offers the benefits of more than 50 unique communities and 18 counties in Kansas and Missouri.  www.thinkKC.com


'/>"/>
SOURCE Kansas City Area Development Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
2. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
3. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
4. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
5. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
6. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
7. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
8. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
9. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
11. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... MAP ... elevated anxiety levels in people with addiction who are served by MAP’s patient ... biosensing wearable device that monitors heart and breath rates to identify anxiety levels ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) ... Jim Walter Blvd, for an educational and exciting 2-day program. , An attendee ... hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each ... published author, Jerri Broglin, a survivor of great loss who gained insight on how ... for those searching for answers, as we are finding the answers that are so ...
(Date:4/24/2017)... Gainesville, Florida (PRWEB) , ... April 24, 2017 , ... ... at the University of Florida. The event will be held at 7:30 pm on ... and Ken Block and Drew Copeland of Sister Hazel, will support the UF Collegiate ...
(Date:4/23/2017)... ... April 23, 2017 , ... "An event Horizon is a place where ... in my Art and Music. These are created as Metaphysical Transformations where music, which ... mystery culminate to the ultimate singularity.", -- Karen Salicath Jamali , Karen will also ...
Breaking Medicine News(10 mins):